Sun Pharma Advanced Research Company Limited

rs,

Kurla Complex, Bandra (East), Mumbai – 400 051. BSE Limited, Market Operations Dept. P. J. Towers, Dalal Street, Mumbai - 400 001. Scrip Symbol: SPARC Scrip Code: 532872 Dear Sir/Madam, Sub:

rs. 2

und by the foregoing limitations. All brand names and trademarks are the property of respective owners. 2 SPARC © 2024 Capital efficient translational engine Maturing operating model with global access to s

70%

of India Shift from 505(b)(2) assets Captive capability – Bench to bedside Founders still own 70% and continue 3 NCEs in clinical development Plugged into global innovation to invest Initi

rs 192

up to 384mg per day Overall well tolerated CSF PK suggests adequate brain penetration over 24 hours 192mg and 384mg doses proposed for Phase 2 PoC study Phase 2 PoC study (PROSEEK) initiated in 2019 PR

40%

olment target Completed enrolment in October 2023 PROSEEK – Global patient distribution 221 Over 40% patients enrolled from the US 89 85 80 21 17 0 50 100 150 200 250 Number of patients ra

1.2%

80 21 17 0 50 100 150 200 250 Number of patients randomized Drug related SAEs reported in 1.2% patients No significant cardiac events reported GI and rash were the most common AEs reported No

60%

-11.6 1 mg -11.4 2 mg -12.7 2-4-6 mg Dose in mg -5.4 -12.1 0.3-0.6-1 mg 0.2-0.6-1 mg ~60% lymphopenia observed at 1mg titrated dose with max HR drop 5.4bpm Lymphopenia at therapeutic dose

50%

in Q4, 2024 AD Phase 3 initiation in Q1, 2025 Vibozilimod is partnered with Sun Pharma with ~50% economics retained with SPARC 16 SPARC © 2024 SCD-153 targeting novel pathway in AA Built on an e

3%

tiple AA models Week# Week 0 (Before treatment) Week 16# Vehicle thrice-a- week SCD-153 at 3% thrice-a- week n=7; 85-100% alopecia; >45 weeks age Spontaneous severe C3H/HeJ AA mouse model n

100%

0 (Before treatment) Week 16# Vehicle thrice-a- week SCD-153 at 3% thrice-a- week n=7; 85-100% alopecia; >45 weeks age Spontaneous severe C3H/HeJ AA mouse model n=4 #n=1 from each group has co

rs 22

multi-modal tumour targeting Synthetic lethality Novel pathways in unaddressed autoimmune disorders 22 SPARC © 2024 SPARC value proposition summary 3 Clinical stage programs targeting areas of high unme

rs 23

xperienced management team and scientific advisory board with globally recongnized scientific leaders 23 SPARC © 2024 SPARC upcoming catalysts NSE/BSE Mumbai India - SPARC 423.35 INR +212.40 (100.69%) pas

Autonomic dysfunction

1

Autonomic dysfunction

Orthostatic hypotension Impaired olfaction Visual abnormalities Sleep disorders Depression Cognitive impairment Pain in medial collateral ligament Dysphagia, Urinary symptoms, Orthostatic hypotension, Dementia -20 -10 0 10 20 Time from diagnosis (years) Treatment Complications Motor symptoms Non-motor symptoms Vodobatinib’s opportunity spectrum Parkinson’s Disease – All stages α synucleinopathies (Lewy Body Dementia & Multi System Atrophy) Diseases driven by other proteins activated by c-Abl (AD, ALS) 70% of PD patients are DMT eligible at diagnosis to delay symptomatic treatment* Physicians expect Vodobatinib to be used across all PD patients, including familial PD* *Based on independent 3rd party research 12 SPARC © 2024 Vibozilimod: best-in-class S1PR1 agonist Safe oral alternative to JAK inhibitors in derma autoimmune disorders S1P functional activity using GTPγS assay S1PR1 agonists Vibozilimod Fingolimod Ozanimod Ponesimod Etrasimod S1PR1 0.2 0.4 1.9 ~1 1.5 EC50 GTPγs (nM) S1PR3